Results 21 to 30 of about 37,814 (299)
ACS Applied Materials and Interfaces, 2023 Retinal neovascularization (RNV) is a typical feature of ischemic retinal diseases that can lead to traction retinal detachment and even blindness in patients, in which the vascular endothelial cell growth factor (VEGF) plays a pivotal role.
Ning Duan +9 more
semanticscholar +1 more source
Assessment of mouse VEGF neutralization by ranibizumab and aflibercept.
PLoS ONE, 2022 PurposeTo assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial growth factor (VEGF), both in vivo and in vitro.MethodsIn vivo, the effect of intravitreal injection of ranibizumab and aflibercept on oxygen induced ...
Yusuke Ichiyama +7 more
doaj +1 more source
Inhibitory effect of tenomodulin versus ranibizumab on in vitro angiogenesis [PDF]
International Journal of Ophthalmology, 2017 AIM: To evaluate anti-angiogenic effect of tenomodulin (TNMD) and ranibizumab on cell proliferation and capillary-like morphogenesis of vascular endothelial cells under the stimulation of vascular endothelial growth factor (VEGF) in vitro.
Wei Wang +4 more
doaj +1 more source
Effect of ranibizumab on retinopathy of prematurity: A meta-analysis
Frontiers in Pharmacology, 2022 The primary objective of this study was to systematically evaluate the clinical efficacy of intravitreal ranibizumab injection in the treatment for retinopathy of prematurity (ROP) in infants.
Zhibin Wang +3 more
semanticscholar +1 more source
6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome [PDF]
International Journal of Ophthalmology, 2016 AIM: To compare visual acuity and central macular thickness (CMT) changes in neovascular age related macular degeneration patients treated with either 6 weekly bevacizumab regimen or 4 weekly ranibizumab on an as required basis.
Patrick J Chiam +3 more
doaj +1 more source
JAMA ophthalmology, 2022 This post hoc analysis of an equivalence trial investigates the association of immunogenicity to ranibizumab products with efficacy, safety, and pharmacokinetics in patients with neovascular age-related macular degeneration.
N. Bressler +5 more
semanticscholar +1 more source
One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study [PDF]
International Journal of Ophthalmology, 2018 AIM: To assess the effectiveness and safety of ranibizumab 0.5 mg in Taiwanese patients with polypoidal choroidal vasculopathy (PCV) by performing a retrospective exploratory subgroup analysis of the REAL study.
San-Ni Chen +8 more
doaj +1 more source
Indian Journal of Ophthalmology, 2022 Purpose: The present study compares the efficacy, safety, and immunogenicity of Lupin’s biosimilar ranibizumab with that of Lucentis® in patients with neovascular age-related macular degeneration.
Ramandeep Singh +10 more
semanticscholar +1 more source
Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. [PDF]
PLoS ONE, 2014 Intravitreal injections of anti-vascular endothelial growth factor agents, such as ranibizumab, have significantly improved the management of neovascular age-related macular degeneration. This study used patient-level simulation modelling to estimate the
Paul Mitchell +9 more
doaj +1 more source
Protective effects on the retina after ranibizumab treatment in an ischemia model. [PDF]
PLoS ONE, 2017 Retinal ischemia is common in eye disorders, like diabetic retinopathy or retinal vascular occlusion. The goal of this study was to evaluate the potential protective effects of an intravitreally injected vascular endothelial growth factor (VEGF ...
Stephanie C Joachim +10 more
doaj +1 more source